pyrazinamide and bedaquiline

pyrazinamide has been researched along with bedaquiline in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (14.29)	29.6817
2010's	24 (57.14)	24.3611
2020's	12 (28.57)	2.80

Authors

Authors	Studies
Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	2
Barry, CE; Dartois, V	1
Andries, K; Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM	1
Andries, K; Gevers, T; Lounis, N; Van Den Berg, J	1
Andries, K; Ibrahim, M; Jarlier, V; Truffot-Pernot, C; Veziris, N	1
Andries, K; Gevers, T; Lounis, N	1
Ackart, D; Basaraba, RJ; Caraway, ML; Hascall-Dove, L; Henao-Tamayo, M; Lenaerts, AJ; Ordway, DJ; Orme, EA; Orme, IM; Shang, S; Shanley, CA	1
Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F	1
Chakraborty, S; Rhee, KY	1
Cole, ST; Dhar, N; Hartkoorn, RC; Lechartier, B; Sala, C; Vocat, A; Zhang, M	1
Diel, R; Gibbert, J; Wirth, D; Wolfson, LJ	1
Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T	1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A	1
Mendel, C; Murray, S; Spigelman, M	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Cao, L; Greenblatt, DJ; Kwara, A	1
Boulle, A; Fox, T; Khomo, N; Kock, Y; Leslie, J; Manning, K; Meintjes, G; Mudaly, V; Stewart, A; Tiffin, N; Wasserman, S; Zhao, Y	1
Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM	1
Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A	1
Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS	1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH	1
Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S	1
Das, SC; Eedara, BB; Momin, MAM; Rangnekar, B; Sinha, S	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Furin, J; McKenna, L	1
Cobelens, F; van den Hof, S; Wang, S; Xia, H; Zhao, B; Zhao, Y; Zhou, Y	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Dhamija, RK; Garg, D; Saroha, D; Singh, AK	1
Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD	1
Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ	1
Chen, K; Fearns, A; Greenwood, DJ; Gutierrez, MG; Jiang, H; Santucci, P	1
Kumari, D; Perveen, S; Sharma, R; Singh, K	1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD	1
Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H	1
Lyons, MA	1
Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC	1
Avihingsanon, A; Balanag, VM; Burhan, E; Chew, KL; Cousins, C; Crook, AM; Dalay, VB; Djaharuddin, I; Kusmiati, T; Lee, SL; Lu, Q; Nunn, AJ; Papineni, P; Paton, NI; Pokharkar, Y; Ruslami, R; Sarin, R; Sekaggya-Wiltshire, C; Sugiri, JJR; Suresh, C; Veto, RS	1

Reviews

4 review(s) available for pyrazinamide and bedaquiline

Article	Year
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Cold Spring Harbor perspectives in medicine, 2015, Apr-15, Volume: 5, Issue:8 Topics: Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Evolution, Chemical; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2015
Development of new drug-regimens against multidrug-resistant tuberculosis. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant	2019
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. European journal of medicinal chemistry, 2022, Feb-05, Volume: 229 Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin	2022

Trials

5 trial(s) available for pyrazinamide and bedaquiline

Article	Year
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8 Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2015
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
Treatment Strategy for Rifampin-Susceptible Tuberculosis. The New England journal of medicine, 2023, Mar-09, Volume: 388, Issue:10 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Linezolid; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2023

Other Studies

33 other study(ies) available for pyrazinamide and bedaquiline

Article	Year
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; Lung; Mice; Organ Size; Pyrazinamide; Quinolines; Spleen; Survival Analysis; Tuberculosis, Pulmonary	2007
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ethionamide; Fluoroquinolones; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Pyrazinamide; Quinolines; Rifampin; Spleen; Survival Analysis; Tuberculosis	2006
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Female; Granuloma; Guinea Pigs; Hypoxia; Isoniazid; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Radiation-Sensitizing Agents; Rifampin; Spleen; Tuberculosis	2007
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Interactions; Female; Humans; Isoniazid; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Spleen; Tuberculosis, Pulmonary	2008
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. American journal of respiratory and critical care medicine, 2009, Jan-01, Volume: 179, Issue:1 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Lung; Mice; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Hydrolases; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Splenic	2009
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2010
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1 Topics: Animals; Antitubercular Agents; Diarylquinolines; Female; Flow Cytometry; Guinea Pigs; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2011
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PloS one, 2012, Volume: 7, Issue:1 Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors	2012
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7 Topics: Adamantane; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Discovery; Ethylenediamines; Genes, Bacterial; Luminescence; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Oxazolidinones; Photorhabdus; Pyrazinamide; Rifamycins; Xanthenes	2015
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany. The European respiratory journal, 2015, Volume: 46, Issue:6 Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Germany; Humans; Markov Chains; Models, Economic; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2016
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:9 Topics: Acetaminophen; Antitubercular Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diarylquinolines; Enzyme Inhibitors; Ethambutol; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Isoenzymes; Isoniazid; Kinetics; Liver; Pyrazinamide; Rifabutin	2017
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-24, Volume: 68, Issue:9 Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; HIV; HIV Infections; Humans; Isoniazid; Isoxazoles; Levofloxacin; Male; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Retrospective Studies; South Africa; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2019
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:12 Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant	2018
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PloS one, 2018, Volume: 13, Issue:11 Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Combinations; Ethylenediamines; Humans; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis	2018
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC infectious diseases, 2019, Sep-09, Volume: 19, Issue:1 Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2019
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International journal of pharmaceutics, 2019, Oct-30, Volume: 570 Topics: A549 Cells; Administration, Inhalation; Aerosols; Antitubercular Agents; Cell Line; Cell Line, Tumor; Chemistry, Pharmaceutical; Diarylquinolines; Drug Compounding; Dry Powder Inhalers; Excipients; Humans; Moxifloxacin; Particle Size; Powders; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC infectious diseases, 2020, Jan-07, Volume: 20, Issue:1 Topics: Adult; Age Factors; Amidohydrolases; Antitubercular Agents; Base Sequence; China; Diarylquinolines; Genes, Bacterial; Genotype; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Point Mutation; Polymorphism, Single Nucleotide; Prevalence; Pyrazinamide; Rifampin; Risk Factors; Tuberculosis, Multidrug-Resistant	2020
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3 Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diarylquinolines; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; Humans; Kanamycin; Linezolid; Neural Conduction; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazinamide; Pyridoxine; Tuberculosis, Pulmonary	2020
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. The Journal of infectious diseases, 2021, 09-17, Volume: 224, Issue:6 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Recurrence; Tuberculosis	2021
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG. International journal of molecular sciences, 2021, Mar-13, Volume: 22, Issue:6 Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide	2021
Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. Nature communications, 2021, 06-21, Volume: 12, Issue:1 Topics: Antitubercular Agents; Cytosol; Diarylquinolines; Drug Synergism; Humans; Hydrogen-Ion Concentration; Macrophages; Microscopy, Electron; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Type VII Secretion Systems	2021
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis	2022
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide. Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling. Clinical pharmacokinetics, 2023, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis	2023